HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lawrence A Leiter Selected Research

Liraglutide

1/2022Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease.
1/2021Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis.
12/2020Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials.
1/2020The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials.
1/2019Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin.
12/2018Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke.
10/2018Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use.
1/2018Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial.
1/2016LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Lawrence A Leiter Research Topics

Disease

176Type 2 Diabetes Mellitus (MODY)
04/2024 - 09/2002
96Cardiovascular Diseases (Cardiovascular Disease)
03/2024 - 01/2003
61Myocardial Infarction
04/2024 - 01/2005
54Heart Failure
12/2023 - 06/2005
41Stroke (Strokes)
04/2024 - 01/2005
29Body Weight (Weight, Body)
05/2024 - 09/2002
29Coronary Artery Disease (Coronary Atherosclerosis)
04/2024 - 08/2002
25Diabetes Mellitus
04/2024 - 01/2002
22Hypertension (High Blood Pressure)
01/2023 - 01/2005
21Dyslipidemias (Dyslipidemia)
12/2023 - 06/2005
20Coronary Disease (Coronary Heart Disease)
01/2024 - 07/2006
20Hypoglycemia (Reactive Hypoglycemia)
01/2023 - 04/2010
17Chronic Renal Insufficiency
04/2024 - 06/2005
17Hypercholesterolemia
12/2023 - 12/2002
16Weight Loss (Weight Reduction)
05/2024 - 09/2010
15Atherosclerosis
04/2024 - 01/2005
14Ischemic Stroke
01/2024 - 11/2012
13Acute Coronary Syndrome
09/2020 - 07/2003
12Albuminuria
01/2021 - 06/2005
10Cerebrovascular Disorders (Cerebrovascular Occlusion)
06/2023 - 05/2007
10Unstable Angina
01/2023 - 01/2005
10Infections
01/2023 - 01/2005
9Metabolic Syndrome (Dysmetabolic Syndrome X)
05/2024 - 01/2007
9Glucose Intolerance
12/2013 - 01/2005
8Hyperlipoproteinemia Type II (Familial Hypercholesterolemia)
11/2023 - 11/2019
8Hyperglycemia
01/2023 - 01/2005
8Overweight
01/2023 - 02/2012
8Kidney Diseases (Kidney Disease)
01/2023 - 07/2011
7Obesity
05/2024 - 11/2010
7Insulin Resistance
07/2020 - 01/2005
7Isolated Systolic Hypertension
01/2017 - 06/2005
5Hemorrhage
04/2024 - 09/2019
5Hyperlipidemias (Hyperlipidemia)
06/2023 - 09/2007
5Prediabetic State (Prediabetes)
01/2022 - 12/2017
5Atrial Fibrillation
01/2022 - 01/2012

Drug/Important Bio-Agent (IBA)

63Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
03/2024 - 07/2003
48Glucose (Dextrose)FDA LinkGeneric
01/2023 - 12/2004
47LipidsIBA
12/2023 - 01/2002
39LDL CholesterolIBA
01/2024 - 05/2005
36oxidized low density lipoproteinIBA
05/2024 - 01/2005
31CholesterolIBA
11/2022 - 12/2002
30dapagliflozinIBA
01/2023 - 07/2014
26Insulin (Novolin)FDA Link
02/2023 - 01/2005
21Sodium-Glucose Transport ProteinsIBA
01/2023 - 09/2013
20omega-Chloroacetophenone (Mace)IBA
04/2024 - 01/2018
17SodiumIBA
01/2023 - 05/2014
16FructoseIBA
01/2023 - 02/2012
15Glucagon-Like Peptide-1 Receptor AgonistsIBA
02/2024 - 01/2016
15Glucagon-Like Peptide 1 (GLP 1)IBA
01/2023 - 11/2016
15Hypoglycemic Agents (Hypoglycemics)IBA
01/2021 - 06/2006
14Glucagon-Like Peptide-1 ReceptorIBA
02/2024 - 08/2014
14Sodium-Glucose Transporter 2 InhibitorsIBA
01/2023 - 09/2013
14Atorvastatin (Lipitor)FDA Link
06/2013 - 01/2003
12Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
04/2024 - 06/2005
12HDL CholesterolIBA
12/2023 - 01/2012
12semaglutideIBA
01/2023 - 11/2016
11Biomarkers (Surrogate Marker)IBA
07/2023 - 05/2007
10ALN-PCSIBA
05/2024 - 01/2017
10Triglycerides (Triacylglycerol)IBA
03/2024 - 12/2010
10Glycated Hemoglobin (Glycosylated Hemoglobin)IBA
02/2023 - 01/2008
10SugarsIBA
01/2023 - 01/2014
10dulaglutideIBA
10/2022 - 01/2018
10CreatinineIBA
01/2022 - 01/2012
10Ezetimibe (Zetia)FDA Link
09/2020 - 01/2003
10Blood Glucose (Blood Sugar)IBA
10/2018 - 09/2002
10Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
01/2018 - 06/2005
9TicagrelorIBA
04/2024 - 05/2019
9empagliflozinIBA
01/2023 - 10/2019
9LiraglutideFDA Link
01/2022 - 01/2016
9Metformin (Glucophage)FDA LinkGeneric
01/2021 - 06/2006
8rGLP-1 proteinIBA
02/2024 - 08/2014
8Proteins (Proteins, Gene)FDA Link
11/2022 - 01/2007
8AlbuminsIBA
01/2022 - 07/2011
8alirocumabIBA
01/2020 - 01/2017
8Angiotensin Receptor AntagonistsIBA
01/2018 - 06/2005
7SymportersIBA
01/2023 - 04/2015
78- hydroxy- 2,2,14,14- tetramethylpentadecanedioic acidIBA
05/2022 - 10/2018
7Insulin Glargine (Lantus)FDA Link
01/2022 - 10/2013
7Rosuvastatin Calcium (Crestor)FDA Link
01/2021 - 10/2007
7Calcium Channel Blockers (Blockers, Calcium Channel)IBA
01/2016 - 06/2005
7Valsartan (Vals)FDA Link
12/2013 - 01/2005
7Nateglinide (Starlix)FDA LinkGeneric
12/2013 - 01/2005
71,4-dihydropyridine (dihydropyridine)IBA
07/2011 - 06/2005
6(2S,3R,4R,5S,6R)- 2- (4- chloro- 3- (4- ethoxybenzyl)phenyl)- 6- (methylthio)tetrahydro- 2H- pyran- 3,4,5- triolIBA
04/2024 - 01/2021
6Proprotein Convertase 9IBA
12/2023 - 01/2017
6CarbohydratesIBA
11/2022 - 01/2008
6saxagliptinFDA Link
11/2021 - 10/2013
6IncretinsIBA
11/2020 - 02/2010
6DiureticsIBA
01/2020 - 05/2007
6CanagliflozinIBA
01/2018 - 09/2013
6Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA
07/2011 - 06/2005
6ThiazidesIBA
05/2010 - 06/2005
5ApolipoproteinsIBA
12/2023 - 09/2002
5HDL LipoproteinsIBA
11/2022 - 11/2012

Therapy/Procedure

77Therapeutics
04/2024 - 01/2003
27Glycemic Control
11/2022 - 09/2002
8Secondary Prevention
06/2023 - 12/2007
7Subcutaneous Injections
01/2021 - 01/2017
6Percutaneous Coronary Intervention
01/2023 - 12/2013
5Surgical Amputation (Amputations)
04/2024 - 01/2020